<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02215863</url>
  </required_header>
  <id_info>
    <org_study_id>FLUPCV13</org_study_id>
    <nct_id>NCT02215863</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years</brief_title>
  <official_title>Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent reviews have highlighted the unpredictability and complexity of immune interference&#xD;
      when multivalent conjugate vaccines are co-administered with other pediatric vaccines. It has&#xD;
      become evident that the likelihood of immune interference (in response to conjugated- or&#xD;
      co-administered antigens) increases in proportional to the number of glyco-conjugates&#xD;
      (valencies) and dosages of carrier proteins. There are many kinds of carrier proteins:&#xD;
      tetanus toxoid (TT), diphtheria toxoid (DT), CRM197 (non-toxic variant of DT), OMP (complex&#xD;
      outer-membrane protein mixture from Neisseria meningitidis) and non-typeable Hemophilus&#xD;
      influenza-derived protein D. Among them, TT is a more potent inducer of T-helper immunity,&#xD;
      but carrier-induced-epitopic suppression (dose-dependent carrier antibody and carrier B cell&#xD;
      dominance) may occur with TT. In comparison, DT and CRM197 are weaker B-cell immunogens, but&#xD;
      apparently trigger more T-regulatory mechanism. Recent pediatric studies of PCV13&#xD;
      co-administered with DTaP vaccines showed 6B GMT (geometric mean titer) to be somewhat&#xD;
      reduced compared to the results with PCV13 alone.&#xD;
&#xD;
      Similar to children, adults frequently visit outpatient clinics to get two or more kinds of&#xD;
      vaccines at the same time: pneumococcal vaccine, influenza vaccine, Td (diphtheria and&#xD;
      tetanus) vaccine, HPV (human papilloma virus) vaccine, meningococcal vaccine, zoster vaccine,&#xD;
      etc. PCV13 has limited co-administration information for adjuvanted influenza vaccine.&#xD;
&#xD;
      This study is designed to evaluate the immunogenicity and safety of PCV13 and MF59-adjuvanted&#xD;
      influenza vaccine (Fluad) after concomitant administration in adults aged 60 years or older.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-centered, randomized controlled clinical trial: Korea University Guro&#xD;
      Hospital, Korea University Ansan Hospital, Hallym University Gangnam Sacred Hospital and&#xD;
      Catholic University Medical College, St. Vincent's Hospital.&#xD;
&#xD;
      The primary objective is to evaluate the immunogenicity of Fluad after concomitant&#xD;
      administration of Fluad and PCV13 in adults aged 60 years or more. This study is designed to&#xD;
      demonstrate non-inferiority of sero-conversion rate after Fluad vaccination: Fluad-PCV13&#xD;
      co-administration group versus Fluad alone group&#xD;
&#xD;
      The secondary objective is to evaluate the immunogenicity of PCV13 after concomitant&#xD;
      administration in adults aged 60 years or more. This study is designed to demonstrate&#xD;
      non-inferiority of PCV13 when co-administered with Fluad compared with PCV13 alone.&#xD;
&#xD;
      This study is also designed to evaluate the safety of concomitant PCV13-Fluad administration&#xD;
      in adults aged 60 years or more. All the participants will be followed for the duration of an&#xD;
      expected average of 4 weeks after vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rates (A/H1N1, A/H3N2, and B)</measure>
    <time_frame>Outcome measure will be assessed at two points (baseline and 4 weeks after vaccination)</time_frame>
    <description>a post-vaccination titer ≥1:40 in subjects with a pre-vaccination titer of &lt;1:10 or a ≥4-fold titer increase in subjects with a pre-vaccination titer of ≥1:10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rates and GMT folds (A/H1N1, A/H3N2, and B)</measure>
    <time_frame>Outcome measure will be assessed at two points (baseline and 4 weeks after vaccination).</time_frame>
    <description>Seroprotection rate: percentage of subjects with a post-vaccination titer ≥1:40&#xD;
GMT-fold change: GMT ratio of the post-vaccination titer to pre-vaccination titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic assay (OPA) titers for PCV13</measure>
    <time_frame>Outcome measure will be assessed at two points (baseline and 4 weeks after vaccination).</time_frame>
    <description>OPA geometric mean titers for 13 PCV13 serotypes with corresponding 2-sided 95% confidence intervals between groups receiving PCV 13 and then compare the results</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency and duration of local and systemic adverse events</measure>
    <time_frame>All participants will be followed until 4 weeks after vaccination)</time_frame>
    <description>The safety profiles of co-administration of Fluad and PCV13 will be compared to those of single vaccination.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1195</enrollment>
  <condition>Influenza</condition>
  <condition>Streptococcus Pneumoniae</condition>
  <arm_group>
    <arm_group_label>PCV13 and Fluad</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>437 concomitant Fluad-PCV13 recipients: one dose of each vaccine administered on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluad alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>437 Fluad recipients: one vaccine injection administered on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCV13 alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>437 PCV13 recipients: one vaccine injection administered on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluad and Prevenar13</intervention_name>
    <arm_group_label>PCV13 and Fluad</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluad</intervention_name>
    <arm_group_label>Fluad alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar13</intervention_name>
    <arm_group_label>PCV13 alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged ≥60 years who signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous pneumococcal vaccine recipients&#xD;
&#xD;
          -  Egg allergy&#xD;
&#xD;
          -  History of serious adverse event after vaccination,&#xD;
&#xD;
          -  any acute disease or infection&#xD;
&#xD;
          -  History of neurological symptoms or signs&#xD;
&#xD;
          -  Impairment of immune function or immunosuppressant use&#xD;
&#xD;
          -  Bleeding diathesis&#xD;
&#xD;
          -  Fever (defined as axillary temperature ³38.0°C) within 3 days (prior to Visit 1)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee Jin Cheong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joon Young Song, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Gangnam Sacred Hospita</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University Medical College, St. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>August 11, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Hee Jin Cheong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Immunogenicity, Safety, MF59, Influenza vaccine, Pneumococcal vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

